Form D · Biotechnology
XCR Diagnostics Inc
Salt Lake City, UT · CIK 0001656921
Offering snapshot reported Oct 16, 2019 · SEC filing
- Reported sold
- $1.8M Offering amount: $2M
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 27, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 16, 2019 | Initial | $1,800,000 | No comparison | 20 | SEC filing |
| Dec 6, 2016 | Amendment | $2,500,000 | No comparison | 0 | SEC filing |
| Mar 18, 2016 | Amendment | $560,000 | No comparison | 0 | SEC filing |
| Dec 8, 2015 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-351107
Source: Form D, filed Oct 16, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Bagnall | Director |
| Ann Marie Buoscio | Executive |
| Brian Caplin | Executive, Promoter |
| Linda Merrill | Director |
| William C Olson | Director, Executive, Promoter |
| Mark Powelson | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4750 Wiley Post Way Suite 110
Salt Lake City, UT, 84116
Salt Lake City, UT, 84116